Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bio Essence (BIOE) Cash & Equivalents (2020 - 2025)

Bio Essence (BIOE) has 6 years of Cash & Equivalents data on record, last reported at $28741.0 in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 3.61% year-over-year to $28741.0; the TTM value through Sep 2025 reached $28741.0, down 3.61%, while the annual FY2024 figure was $1371.0, 1102.63% up from the prior year.
  • Cash & Equivalents reached $28741.0 in Q3 2025 per BIOE's latest filing, up from $1371.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $29818.0 in Q3 2024 and bottomed at $23.0 in Q1 2024.
  • Average Cash & Equivalents over 5 years is $7234.6, with a median of $572.0 recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: crashed 98.53% in 2022, then soared 33403.37% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $303.0 in 2021, then skyrocketed by 1966.67% to $6262.0 in 2022, then tumbled by 98.18% to $114.0 in 2023, then soared by 1102.63% to $1371.0 in 2024, then soared by 1996.35% to $28741.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $28741.0 in Q3 2025, $1371.0 in Q4 2024, and $29818.0 in Q3 2024.